Aminomethyl-benzoaquinolizidine derivatives, preparation and therapeutic applications for neurodegenrative diseases
CA 2307748 A1 · Owner: Imbert, Thierry · Inventors: Vidaluc, Jean-Louis; Marien, Marc; Imbert, Thierry
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns 2-aminomethyl-benzoaquinolizidine derivatives corresponding to general formula (I) in which: R¿1? represents either a hydrogen atom or a branched linear or cyclic C¿1?-C¿4? alkyl group a branched, linear or cyclic C¿1?-C¿4? hydroxy or alkoxy group or a halogen atom such as F or Cl; R¿2? represents a hydrogen atom or a C¿1?-C¿6? alkyl group; R¿3? represents a hydrogen atom or can constitute a unit (C=X)-NR¿4?R¿5? and in that case constitutes a urea or thiourea with X = oxygen or sulphur; R¿4? and R¿5? can independently be a hydrogen atom or a linear branched, cyclic C¿1?-C¿8? alkyl group an aryl, aralkyl, aroyl group, said aryl groups capable of being substituted as …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 26, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 26, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 26, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.